| Defining high, medium and low impact prognostic factors for developing multiple sclerosis M Tintore, À Rovira, J Río, S Otero-Romero, G Arrambide, C Tur, ... Brain 138 (7), 1863-1874, 2015 | 622 | 2015 |
| MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis--establishing disease prognosis and monitoring patients MP Wattjes, À Rovira, D Miller, TA Yousry, MP Sormani, N De Stefano, ... Nature Reviews Neurology 11 (10), 597-607, 2015 | 581 | 2015 |
| MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—clinical implementation in the diagnostic process À Rovira, MP Wattjes, M Tintoré, C Tur, TA Yousry, MP Sormani, ... Nature Reviews Neurology 11 (8), 471-482, 2015 | 508 | 2015 |
| Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis? M Tintoré, A Rovira, J Rio, C Tur, R Pelayo, C Nos, N Téllez, H Perkal, ... Neurology 70 (13_part_2), 1079-1083, 2008 | 469 | 2008 |
| Deep gray matter volume loss drives disability worsening in multiple sclerosis A Eshaghi, F Prados, WJ Brownlee, DR Altmann, C Tur, MJ Cardoso, ... Annals of neurology 83 (2), 210-222, 2018 | 448 | 2018 |
| Progression of regional grey matter atrophy in multiple sclerosis A Eshaghi, RV Marinescu, AL Young, NC Firth, F Prados, ... Brain 141 (6), 1665-1677, 2018 | 385 | 2018 |
| Neurite dispersion: a new marker of multiple sclerosis spinal cord pathology? F Grussu, T Schneider, C Tur, RL Yates, M Tachrount, A Ianuş, ... Annals of clinical and translational neurology 4 (9), 663-679, 2017 | 325 | 2017 |
| Association of autonomic dysfunction with disease progression and survival in Parkinson disease E De Pablo-Fernandez, C Tur, T Revesz, AJ Lees, JL Holton, TT Warner JAMA neurology 74 (8), 970-976, 2017 | 224 | 2017 |
| Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting C Tur, M Moccia, F Barkhof, J Chataway, J Sastre-Garriga, AJ Thompson, ... Nature Reviews Neurology 14 (2), 75-93, 2018 | 169 | 2018 |
| Relationship between MRI lesion activity and response to IFN-β in relapsing–remitting multiple sclerosis patients J Rio, A Rovira, M Tintoré, E Huerga, C Nos, N Tellez, C Tur, ... Multiple Sclerosis Journal 14 (4), 479-484, 2008 | 160 | 2008 |
| Fatigue management in multiple sclerosis C Tur Current treatment options in neurology 18, 1-12, 2016 | 157 | 2016 |
| Reduced gamma-aminobutyric acid concentration is associated with physical disability in progressive multiple sclerosis N Cawley, BS Solanky, N Muhlert, C Tur, RAE Edden, ... Brain 138 (9), 2584-2595, 2015 | 155 | 2015 |
| Association of early progression independent of relapse activity with long-term disability after a first demyelinating event in multiple sclerosis C Tur, P Carbonell-Mirabent, Á Cobo-Calvo, S Otero-Romero, ... JAMA neurology 80 (2), 151-160, 2023 | 146 | 2023 |
| Neurofilament light chain level is a weak risk factor for the development of MS G Arrambide, C Espejo, H Eixarch, LM Villar, JC Alvarez-Cermeño, ... Neurology 87 (11), 1076-1084, 2016 | 132 | 2016 |
| Spinal cord lesions: a modest contributor to diagnosis in clinically isolated syndromes but a relevant prognostic factor G Arrambide, A Rovira, J Sastre-Garriga, C Tur, J Castilló, J Río, ... Multiple Sclerosis Journal 24 (3), 301-312, 2018 | 119 | 2018 |
| Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes A Vidal-Jordana, J Sastre-Garriga, F Pérez-Miralles, C Tur, M Tintoré, ... Multiple Sclerosis Journal 19 (9), 1175-1181, 2013 | 117 | 2013 |
| Value of the central vein sign at 3T to differentiate MS from seropositive NMOSD R Cortese, L Magnollay, C Tur, K Abdel-Aziz, A Jacob, F De Angelis, ... Neurology 90 (14), e1183-e1190, 2018 | 101 | 2018 |
| Longitudinal evidence for anterograde trans-synaptic degeneration after optic neuritis C Tur, O Goodkin, DR Altmann, TM Jenkins, K Miszkiel, A Mirigliani, C Fini, ... Brain 139 (3), 816-828, 2016 | 97 | 2016 |
| Mind the gap: from neurons to networks to outcomes in multiple sclerosis DT Chard, AAS Alahmadi, B Audoin, T Charalambous, C Enzinger, ... Nature Reviews Neurology 17 (3), 173-184, 2021 | 89 | 2021 |
| Disability progression markers over 6–12 years in interferon-β-treated multiple sclerosis patients J Río, À Rovira, M Tintoré, S Otero-Romero, M Comabella, ... Multiple Sclerosis Journal 24 (3), 322-330, 2018 | 82 | 2018 |